These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23299001)

  • 41. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Syncope after vaccination--United States, January 2005-July 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 May; 57(17):457-60. PubMed ID: 18451756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1391-2. PubMed ID: 21993344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
    Read RC; Baxter D; Chadwick DR; Faust SN; Finn A; Gordon SB; Heath PT; Lewis DJ; Pollard AJ; Turner DP; Bazaz R; Ganguli A; Havelock T; Neal KR; Okike IO; Morales-Aza B; Patel K; Snape MD; Williams J; Gilchrist S; Gray SJ; Maiden MC; Toneatto D; Wang H; McCarthy M; Dull PM; Borrow R
    Lancet; 2014 Dec; 384(9960):2123-31. PubMed ID: 25145775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Oct; 54(40):1023-5. PubMed ID: 16224452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.
    Tregnaghi M; Lopez P; Stamboulian D; Graña G; Odrljin T; Bedell L; Dull PM
    Int J Infect Dis; 2014 Sep; 26():22-30. PubMed ID: 24980467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
    MacNeil JR; Rubin LG; Patton M; Ortega-Sanchez IR; Martin SW
    MMWR Morb Mortal Wkly Rep; 2016 Nov; 65(43):1189-1194. PubMed ID: 27811836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
    Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
    J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.
    Welsch JA; Senders S; Essink B; Klein T; Smolenov I; Pedotti P; Barbi S; Verma B; Toneatto D
    Vaccine; 2018 Aug; 36(35):5309-5317. PubMed ID: 30061029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix
    Dhillon S; Pace D
    Drugs; 2017 Nov; 77(17):1881-1896. PubMed ID: 29094312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents.
    Serra LC; York LJ; Balmer P; Webber C
    J Adolesc Health; 2018 Sep; 63(3):269-279. PubMed ID: 30236996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.
    MacNeil JR; Rubin L; McNamara L; Briere EC; Clark TA; Cohn AC;
    MMWR Morb Mortal Wkly Rep; 2014 Jun; 63(24):527-30. PubMed ID: 24941332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence.
    Findlow J; Knuf M
    Future Microbiol; 2019 May; 14():563-580. PubMed ID: 31091978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.
    Gill CJ; Baxter R; Anemona A; Ciavarro G; Dull P
    Hum Vaccin; 2010 Nov; 6(11):881-7. PubMed ID: 21339701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
    Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
    JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
    Østergaard L; Van der Wielen M; Bianco V; Miller JM
    Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Meyer S; Forleo-Neto E; Gniel D; Dagnew AF; Arora AK
    Travel Med Infect Dis; 2014; 12(5):485-93. PubMed ID: 24873986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jan; 62(3):52-4. PubMed ID: 23344698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.